Literature DB >> 25383844

Use of intravitreal triamcinolone for the treatment of optic nerve edema in a patient with acute retinal necrosis: case report.

Patrick D Munson1, Mark L Nelson, Courtney Crawford, Bruce A Rivers, Paula E Young.   

Abstract

PURPOSE: To report the use of combined intravitreal triamcinolone and foscarnet therapy in a patient with active acute retinal necrosis.
METHODS: Retrospective case report. A 40-year-old white woman with a history of ulcerative proctitis, intolerant to oral steroids, developed an aggressive case of acute retinal necrosis complicated by severe optic nerve edema resulting in 20/200 vision.
RESULTS: Intravitreal foscarnet provided an initial improvement of the vitritis and retinitis; however, optic nerve edema and 20/200 vision persisted. After 2 weeks, intravitreal triamcinolone was combined with the foscarnet dose. Four days later, the optic nerve edema had resolved, the vision returned to 20/40, and the herpetic infection remained controlled. Eight months later, the patient had not experienced a retinal detachment, and acuity was 20/20. Oral steroids are an accepted adjunct to antiviral therapy in acute retinal necrosis; however, combined intravitreal steroid and antiviral therapy has not been previously reported. After combined intravitreal therapy was attempted, the patient experienced a rapid resolution of symptoms without exacerbating her retinitis.
CONCLUSION: In select patients, combined intravitreal triamcinolone and foscarnet may be effective in treating acute retinal necrosis and its inflammatory sequelae.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25383844     DOI: 10.1097/ICB.0000000000000100

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  1 in total

1.  Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis.

Authors:  Parthopratim Dutta Majumder; Jyotirmay Biswas; Asra Ambreen; Rowayda Amin; Zahedur Rahman Pannu; Ahmed Magdy Bedda
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-12-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.